Literature DB >> 20118977

Chemotherapy: continued lack of progress in SCLC.

Janakiraman Subramanian, Ramaswamy Govindan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118977     DOI： 10.1038/nrclinonc.2009.223

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Authors:  Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

2.  Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

Authors:  Mark A Socinski; Charles Weissman; Lowell L Hart; J Thaddeus Beck; Janak K Choksi; John P Hanson; Diane Prager; Matthew J Monberg; Zhishen Ye; Coleman K Obasaju
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

3.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors:  Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

4.  Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

Authors:  Akira Inoue; Shunichi Sugawara; Koichi Yamazaki; Makoto Maemondo; Toshiro Suzuki; Kazunori Gomi; Shingo Takanashi; Chieko Inoue; Minoru Inage; Hiroshi Yokouchi; Hiroshi Watanabe; Toumei Tsukamoto; Yasuo Saijo; Osamu Ishimoto; Fumihiro Hommura; Toshihiro Nukiwa
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

5.  Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.

Authors:  Shadia Jalal; Rafat Ansari; Ramaswamy Govindan; Sumeet Bhatia; Daniel Bruetman; William Fisher; Gregory Masters; Angela White; Daniel Stover; Menggang Yu; Nasser Hanna
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

6.  A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

Authors:  Bjørn H Grønberg; Roy M Bremnes; Ulf Aasebø; Paal Brunsvig; Oystein Fløtten; Tore Amundsen; Christian von Plessen; Mari Wang; Stein Sundstrøm
Journal:  Lung Cancer       Date:  2008-06-06       Impact factor: 5.705

7.  A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.

Authors:  A Inoue; O Ishimoto; S Fukumoto; K Usui; T Suzuki; H Yokouchi; M Maemondo; M Kanbe; S Ogura; T Harada; S Oizumi; M Harada; S Sugawara; T Fukuhara; T Nukiwa
Journal:  Ann Oncol       Date:  2009-10-13       Impact factor: 32.976

8.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

9.  Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Authors:  Mark A Socinski; Egbert F Smit; Paul Lorigan; Kartik Konduri; Martin Reck; Aleksandra Szczesna; Johnetta Blakely; Piotr Serwatowski; Nina A Karaseva; Tudor Ciuleanu; Jacek Jassem; Mircea Dediu; Shengyan Hong; Carla Visseren-Grul; Axel-Rainer Hanauske; Coleman K Obasaju; Susan C Guba; Nick Thatcher
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  9 in total
  2 in total

1.  Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.

Authors:  Konstantinos Kerkentzes; Vincenzo Lagani; Ioannis Tsamardinos; Mogens Vyberg; Oluf Dimitri Røe
Journal:  Front Oncol       Date:  2014-09-29       Impact factor: 6.244

2.  Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.

Authors:  Fabian Doerr; Julie George; Anna Schmitt; Filippo Beleggia; Tim Rehkämper; Sarah Hermann; Vonn Walter; Jean-Philip Weber; Roman K Thomas; Maike Wittersheim; Reinhard Büttner; Thorsten Persigehl; H Christian Reinhardt
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.